Immunic, Inc. to Participate in Investor Conferences in September
Immunic, Inc. (Nasdaq: IMUX) announced its participation in several investor conferences throughout September 2022. Key events include the Citi's 17th Annual BioPharma Conference on September 7-8 in Boston, where CEO Daniel Vitt and Head of Investor Relations Jessica Breu will attend. The Wells Fargo 2022 Healthcare Conference will feature Dr. Vitt in a fireside chat on September 9 at 9:45 am EDT, with a live broadcast available on the company's website. Additionally, Breu will present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29 at 1:00 pm EDT in New York.
- None.
- None.
NEW YORK, Sept. 1, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor conferences in September:
- September 7-8: Citi's 17th Annual BioPharma Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, and Jessica Breu, Head of Investor Relations and Communications at Immunic, will attend Citi's 17th Annual BioPharma Conference in Boston.
- September 7-9: Wells Fargo 2022 Healthcare Conference. Dr. Vitt will participate in a fireside chat at the Wells Fargo 2022 Healthcare Conference in Boston on Friday, September 9, 2022 at 9:45 am EDT. A live webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. An archived replay will be available on the company's website for a period of 90 days after the conference.
- September 29: 2022 Ladenburg Thalmann Healthcare Conference. Jessica Breu will present a company overview at the 2022 Ladenburg Thalmann Healthcare Conference in New York on Thursday, September 29 at 1:00 pm EDT. A live webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. An archived replay will be available on the company's website for a period of 90 days after the conference.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγ/RORγt, is targeted for development in psoriasis, and castration-resistant prostate cancer. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit: www.imux.com.
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, expected timing and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's participation in investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, impacts of the Ukraine-Russia conflict, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on February 24, 2022, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 617 974 8659
kaplan@kogspr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-inc-to-participate-in-investor-conferences-in-september-301616125.html
SOURCE Immunic, Inc.
FAQ
What investor conferences is Immunic participating in September 2022?
Who from Immunic will attend the Citi BioPharma Conference?
When is Immunic's presentation at the Wells Fargo Healthcare Conference?
Where and when will Immunic present at the Ladenburg Thalmann Healthcare Conference?
